IGI Logo

Venus Remedies is currently trading at Rs. 244.20, up by 11.55 points or 4.96% from its previous closing of Rs. 232.65 on the BSE.

The scrip opened at Rs. 223.30 and has touched a high and low of Rs. 244.25 and Rs. 222.45 respectively. So far 8732 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 301.80 on 10-Jul-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023.

Last one week high and low of the scrip stood at Rs. 251.05 and Rs. 222.00 respectively. The current market cap of the company is Rs. 326.42 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 0.98% and 57.26% respectively.

Venus Remedies has received marketing approval from Saudi Arabia, the largest pharmaceutical market in the Gulf Cooperation Council (GCC) region, for its product Enoxaparin in pre-filled syringes. The company has an annual capacity of producing more than 5 million units of Enoxaparin, a widely used anticoagulant that prevents blood clots, at its robotic line. Having secured marketing authorizations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products, Venus Remedies has so far sold more than 12 million units of drugs in the $7.8-billion Saudi Arabian pharmaceutical market (as in 2021), which is expected to grow to $13.1 billion by 2031 at a 10-year CAGR of 5.4 per cent. 

The marketing approval for Enoxaparin from Saudi Arabia, the leading country in the Gulf region in terms of quality benchmarks as well, is expected to soon pave the way for grant of marketing authorizations to Venus Remedies for the drug from other countries in GCC and Middle East and North Africa (MENA) regions where the submissions have already been made and consider the Saudi Food and Drug Authority (SFDA) as a reference authority.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.